Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 24;76(10):1850-1853.
doi: 10.1093/cid/ciad021.

Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women

Peter L Anderson  1 , Mark A Marzinke  2   3 , David V Glidden  4
Affiliations

Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women

Peter L Anderson et al. Clin Infect Dis. .

Abstract

Using intraerythrocytic tenofovir-diphosphate data from the emtricitabine/tenofovir disoproxil fumarate arms of HIV Prevention Trials Network (HPTN) 083 (men) and HPTN 084 (women), approximately 99% efficacy was achieved at a lower adherence threshold in HPTN 083 (≥2 doses/week) compared with HPTN 084 (daily), suggesting higher adherence is necessary for women vs men.

Keywords: PrEP; adherence; pharmacology; sex differences; tenofovir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. D. V. G. has received consulting fees from Gilead and grants or contracts unrelated to this work from the NIH paid to institution. P. L. A. has received consulting fees from Merck, ViiV, and Gilead and research support from Gilead paid to institution. M. A. M. has received research support from Merck, ViiV, Ridgeback, and Gilead paid to institution; royalties from Elsevier as co-editor of a textbook; honoraria for speaking engagements from Bio-Rad; and travel support from MSACL and AACC and has a leadership or fiduciary role on the board of directors of AACC. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Percentage HIV risk-reduction estimates (y-axis) for HPTN 083 and HPTN 084 according to adherence as measured with TFV-DP at or near the seroconversion visit (x-axis). Point estimates and 95% CIs are included on the x-axis. For HPTN 083, person-years (number of infections), from left to right, were 274 (24), 290 (13), 316 (0), 1235 (0), and 1072 (2). For HPTN 084, person-years (number of infections), from left to right, were 738 (21), 505 (12), 350 (2), 291 (1), 58 (0). Abbreviations: BLQ, Below the Limit of Quantification; CI, confidence interval; DBS, dried blood spot; HIV, human immunodeficiency virus; HPTN, HIV Prevention Trials Network; TFV-DP, tenofovir diphosphate.
See this image and copyright information in PMC

References

    1. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022; 399:1779–89. - PMC - PubMed
    1. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021; 385:595–608. - PMC - PubMed
    1. Eshleman SH, Fogel JM, Piwowar-Manning E, et al. Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate/emtricitabine for HIV prevention: HPTN 084. J Infect Dis 2022; 225:1741–9. - PMC - PubMed
    1. Marzinke MA, Grinsztejn B, Fogel JM, et al. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis 2021; 224:1581–92. - PMC - PubMed
    1. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4. - PMC - PubMed

Publication types